Trial register facet
Trial records for Exenatide
36 records for Exenatide, of which 7 are published trials.
Showing 0 records on this page
Records
36 documents · page 1 of 2
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| EXENATIDE-GE-PD | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 194 | 2025 | Moderate |
| EXENATIDE-GE-PD-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| EXENATIDE-GE-PD-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| AMPLITUDE-O-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| EXSCEL | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 14,752 | 2017 | High |
| EXSCEL-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EMBRACE-STEMI | Exenatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 91 | 2016 | Moderate |
| EMBRACE-STEMI-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| EMBRACE-STEMI-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2016 | Very low |
| EMBRACE-STEMI-PKprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| EMBRACE-STEMI-RENAL-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| EMBRACE-STEMI-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| DURATION-6 | Exenatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 911 | 2013 | High |
| DURATION-6-BIOMARKERprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| DURATION-6-ADHERENCEprogramme record | Exenatide | Phase 3 | Reported | Observational | — | 2013 | Very low |
| DURATION-6-OLEprogramme record | Exenatide | Phase 3 | Reported | Single-arm open-label | — | 2013 | Very low |
| DURATION-6-ELDERLYprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| DURATION-6-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
page 1 of 2